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Abstract
A new vaccination strategy is urgently needed for improved control of the global tuberculosis (TB) epidemic. Using a mouse
aerosol Mycobacterium tuberculosis challenge model, we investigated the protective efficacy of a mmaA4 gene deletion
mutant of Mycobacterium bovis BCG (DmmaA4BCG) formulated in dimethyl dioctadecyl ammonium bromide (DDA) – D(+)
trehalose 6,6 dibenenate (TDB) (DDA/TDB) adjuvant. In previous studies, deletion of the mmaA4 gene was shown to reduce
the suppression of IL-12 production often seen after mycobacterial infections. While the non-adjuvanted DmmaA4BCG
strain did not protect mice substantially better than conventional BCG against a tuberculous challenge in four protection
experiments, the protective responses induced by the DmmaA4BCG vaccine formulated in DDA/TDB adjuvant was
consistently increased relative to nonadjuvanted BCG controls. Furthermore, the DmmaA4BCG-DDA/TDB vaccine induced
significantly higher frequencies of multifunctional (MFT) CD4 T cells expressing both IFNc and TNFa (double positive) or
IFNc, TNFa and IL-2 (triple positive) than CD4 T cells derived from mice vaccinated with BCG. These MFT cells were
characterized by having higher IFNc and TNFa median fluorescence intensity (MFI) values than monofunctional CD4 T cells.
Interestingly, both BCG/adjuvant and DmmaA4BCG/adjuvant formulations induced significantly higher frequencies of CD4 T
cells expressing TNFa and IL-2 than nonadjuvanted BCG or DmmaA4BCG vaccines indicating that BCG/adjuvant mixtures
may be more effective at inducing central memory T cells. Importantly, when either conventional BCG or the mutant were
formulated in adjuvant and administered to SCID mice or immunocompromised mice depleted of IFNc, significantly lower
vaccine-derived mycobacterial CFU were detected relative to immunodeficient mice injected with non-adjuvanted BCG.
Overall, these data suggest that immunization with the DmmaA4BCG/adjuvant formulation may be an effective, safe, and
relatively inexpensive alternative to vaccination with conventional BCG.
Citation: Derrick SC, Dao D, Yang A, Kolibab K, Jacobs WR, et al. (2012) Formulation of a mmaA4 Gene Deletion Mutant of Mycobacterium bovis BCG in Cationic
Liposomes Significantly Enhances Protection against Tuberculosis. PLoS ONE 7(3): e32959. doi:10.1371/journal.pone.0032959
Editor: Homayoun Shams, University of Texas at Tyler, United States of America
Received June 3, 2011; Accepted February 8, 2012; Published March 19, 2012
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: steven.derrick@fda.hhs.gov
Introduction
Despite being an ancient disease, TB remains an enormous
public health concern in the 21
st century. One-third of the world’s
population is thought to be infected with Mycobacterium tuberculosis
and new infections likely occur every second. In 2009, the World
Health Organization estimated that there were 14 million active
cases of TB, 9.4 million new cases, and 1.7 million deaths due to
this disease [1]. A driving force for the resurgent TB epidemic has
been the HIV/AIDS pandemic. It has been estimated that
approximately 1.5 million individuals are co-infected with TB and
HIV and more than 400,000 co-infected persons die each year [2].
Importantly, control of this epidemic has been further confounded
by the emergence of multiple drug resistant and extensively drug-
resistant M. tuberculosis strains which often limit treatment options
and make appropriate medical interventions challenging [3].
The only licensed vaccine against TB, M. bovis BCG, has been
given to over 3 billion persons during its eight decades of clinical
use. Randomized controlled trials and retrospective case control
studies have shown that BCG immunization is effective in
reducing cases of severe disseminated tuberculosis (TB meningitis
and miliary TB) in children [4,5]. Surprisingly, recent studies have
also suggested that BCG vaccination may also reduce the risk of
childhood infection by M. tuberculosis [6–8]. However, the
effectiveness of BCG vaccine in preventing the most contagious
and prevalent form of disease, pulmonary TB, is unclear. BCG-
induced protection against TB has been highly variable with
protective efficacies ranging from 0–80% in numerous clinical
trials [4,9]. Furthermore, the protection induced by BCG
vaccination is often not highly persistent and a substantial waning
of the protective responses is generally seen during the first decade
after immunization [10]. Given the devastation of the global TB
epidemic, the sub-optimal effectiveness of BCG immunization has
created a public health urgency to generate an improved TB
vaccination strategy.
Since BCG is widely used in areas where the TB burden is high
and BCG immunization does reduce the incidence of severe
extrapulmonary disease in children, the current focus of many TB
vaccinologists has been the development of an approach to amplify
BCG-induced immune responses by boosting with viral vectored
or subunit TB vaccines after the priming BCG immunization
[11,12]. Although the prime/boost strategy is clearly promising,
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cost of subunit vaccines may limit its utility in developing
countries. Alternative simpler and less expensive approaches
may be required in the development of an improved TB
vaccination strategy for the developing world. At least two of
these TB vaccine improvement approaches have concentrated on
modifying conventional BCG vaccine formulations. For example,
encapsulation of BCG in lipid preparations has been shown in
mice, badgers, guinea pigs, and cattle to improve the immuno-
genicity and protective efficacy of BCG immunization [13–18].
Lipid encapsulation of BCG seems to increase the extent and
kinetics of BCG infection at specific immune sites including the
lymph nodes. Secondly, BCG strains are being modified to
enhance their immunogenicity [19–20]. Interestingly, more
immunogenic mycobacterial strains have been generated using
genetic approaches to remove mycobacterial genes known to
inhibit host pro-inflammatory responses. Recently, Dao and
colleagues have shown that a deletion in the mmaA4 gene (which
encodes a methyl transferase involved in mycolic acid synthesis) of
M. tuberculosis removed the selective repression of IL-12 synthesis
caused by mycobacterial infections. As a result, the DmmaA4
mutant strain induced significantly elevated levels of this critical
Th1-type cytokine in macrophage cultures [21].
Here we have combined two BCG modification approaches in
the evaluation of a novel immunization strategy against TB.
Specifically, we created a DmmaA4 mutant of BCG and formulated
it in the DDA/TDB cationic liposomal adjuvant. This adjuvant
has been shown to be safe and immune enhancing in human
clinical trials, [22]. We then evaluated the immunogenicity, safety,
and effectiveness of this preparation in a mouse model of
pulmonary TB. Our data suggests that this mutant BCG/adjuvant
formulation induces higher levels of mycobacterial-specific multi-
functional T cells, is more protective than BCG vaccine, and,
surprisingly, may be safer than BCG when used in immunocom-
promised animals.
Materials and Methods
Animals
C57BL/6 female mice and SCID mice (B6.CB17-
Prkdc,scid.SzJ; # 25938) that were 6–8 weeks of age were
obtained from the Jackson Laboratories (Bar Harbour, Maine). All
mice used in this study were maintained under appropriate
conditions at the Center for Biologics Evaluation and Research,
Bethesda, MD. This study was done in accordance with the
guidelines for the care and use of laboratory animals specified by
the National Institutes of Health. This protocol was approved by
the Institutional Animal Care and Use Committee of the Center
for Biologics Evaluation and Research under Animal Study
Protocol 1993-09.
Preparation of vaccines
The DmmaA4BCG mutant was derived from BCG Pasteur as
previously described [21]. Wild-type BCG Pasteur or the
DmmaA4BCG strain were administered subcutaneously (s.c.) in
PBS or adjuvant at 1610
6 CFU per immunization in 0.2 ml. The
adjuvant- containing vaccines were prepared by mixing the BCG
or the mutant BCG with dimethyl dioctadecyl-ammonium
bromide (DDA, Kodak, Rochester, NY) and D-(+)-Trehalose
6,69-Dibehenate (TDB, Avanti Polar Lipids, Alabster, AL). The
DDA solution was prepared by heating 25 mg in 10 ml water at
80uC for 20 min and vortexing every 5 minutes. The TDB
solution was prepared by adding 1.0 ml of water with 2 ml DMSO
(0.2% final) to a vial containing 5.0 mg TDB. The TDB
suspension was sonicated until it became homogenous. The
adjuvanted vaccines were prepared by mixing 5610
6 CFU of
BCG or the mutant BCG strain with 0.6 ml of DDA with
sufficient PBS to bring the volume to 0.9 ml. One-tenth ml of
TDB was added to the BCG-DDA mixture, vortexed three times
and then incubated at room temperature for 1 hour. Mice
received either one immunization or three immunizations 2 weeks
apart.
Evaluation of vaccine-induced protective immunity in a
murine model of pulmonary TB
At 2 months after the final immunization, five mice per group
were infected with M. tuberculosis Erdman by aerosol at a
concentration known to deliver about 200 CFU in the lungs over
a 30-minute exposure in a Middlebrook chamber (Glas Col, Terre
Haute, IN) [23]. At each time point, the lungs and spleens were
homogenized separately in PBS with 0.05% Tween 80 using a
Seward Stomacher 80 blender (Tekmar, Cincinnati, OH). The
homogenates were serially diluted in PBS +0.05% Tween 80 and
plated on Middlebrook 7H11 agar (Difco) plates containing 10%
OADC enrichment (Becton Dickinson, Sparks, MD) medium,
10 mg/ml ampicillin, 50 mg/ml cycloheximide, and 2 mg/ml 2-
thiophenecarboxylic acid hydride (TCH) (Sigma). The addition of
TCH to the agar plates inhibits BCG growth but has no effect on
M. tuberculosis growth. Plates were incubated at 37uC for 17 days
before counting to determine the number of mycobacterial colony
forming units (CFU) per organ.
Evaluation of the safety of BCG or DmmaA4BCG with or
without adjuvant in immunocompromised mice
To evaluate the safety of the different BCG vaccine prepara-
tions, we used either mice treated with anti-IFNc neutralizing
antibody or SCID mice. For the studies in mice receiving the anti-
IFNc antibody treatment, mice received intraperitoneal injections
of anti-IFNc (XMG.6) (0.5 mg) at 4 and 2 days prior to receiving
one s.c. injection of 1610
6 CFU of BCG or DmmaA4BCG with or
without adjuvant. The mice received antibody treatments every 10
days and were then sacrified one month after being infected for
evaluation of spleen bacterial burdens. SCID mice received one
10
6 CFU dose of the different BCG vaccine preparations
intravenously (i.v.) and were then sacrificed one month later to
quantify bacterial CFU in the spleens.
Flow Cytometry
Four to five unchallenged mice were used to determine the
frequency of CD4+ or CD8+ multifunctional T cells (MFT cells)
induced for each vaccine at 2 months post-immunization.
Unvaccinated (naı ¨ve) mice served as the negative control. Spleen
cells from naı ¨ve and vaccinated mice were isolated by disrupting
the spleens using a 3cc syringe barrel in complete DMEM
(cDMEM) consisting of 10 mM HEPES, 2.0 mM L-glutamine,
0.1 mM MEM non-essential amino acids with 10% fetal bovine
serum (FBS). After passing the spleen homogenates through a
70 mm cell strainer, the resulting single cell suspension was washed
with cDMEM and treated for 1 min with 5.0 ml ACK lysing
buffer (Lonza, Walkersville, MD). After washing the spleen cells
with an equal volume of media, the cells were resuspended in
cDMEM and added to wells of a 24-well plate at a density of
2.5610
6 cells per well in 1.0 ml. For measurement of antigen-
specific responses, BCG Pasteur was added to the wells at a
multiplicity of infection (MOI) of 0.5 bacilli per spleen cell. Wells
which contained only spleen cells served as unstimulated controls.
After an overnight incubation, Golgiplug (BD Biosciences, San
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incubated 4 hours. Unbound cells were removed from the wells
and transferred to 12675 mm tubes, washed with PBS and
resuspended in 50 ml PBS. Live-Dead stain (Invitrogen, Carlsbad,
CA) (10 ml of a 1:100 dilution) was added to each tube and
incubated for 30 min. at 4uC to allow for gating on viable cells.
After washing the cells with PBS-FBS, antibody against CD16/
CD32 (FccIII/II receptor, clone 2.4G2) (Fc block) was added in a
volume of 50 ml and incubated at 4uC for 15 min. The cells were
then stained for 30 min. at 4uC by adding antibodies against the
CD4 (rat anti-mouse CD4 Alexa Fluor 700 [AF-700] Ab, clone
RM4-5), and CD8 (rat anti-mouse CD8 peridinin chlorophyll
protein complex [PerCP] Ab, clone 53-6.7) proteins at 0.1 and
0.4 mg per tube respectively. Following the incubation, the cells
were washed twice with PBS and then fixed for 30 min. at 4uC
with 2% paraformaldehyde in PBS. After fixing, the cells were
pelleted, washed twice with PBS-FBS and stored at 4uC. Fixed
cells were washed twice with perm-wash buffer (1% FBS, 0.01 M
HEPES, 0.1% saponin in PBS) followed by intracellular staining
using the following antibodies at 0.2 mg per tube: rat anti-mouse
IFNc allophycocyanin [APC] Ab, clone XMG1.2; rat anti-mouse
TNFa fluorescein isothiocyanate [FITC] Ab, clone MP6-XT22;
rat anti-mouse IL-2 phycoerythrin [PE] Ab, clone JES6-5H4. The
cells were incubated at 4uC for 30 min., washed twice with perm-
wash buffer and then twice with PBS-FBS. All antibodies were
obtained from BD Biosciences.
The cells were analyzed using a LSRII flow cytometer (Becton
Dickinson) and FlowJo software (Tree Star Inc., Ashland, Oregon).
We acquired 250,000 events per sample and then, using FlowJo,
gated on live, single cell lymphocytes. To determine the frequency
of different populations of MFT cells, we gated on CD4 or CD8 T
cells staining positive for TNFa and IFNc, TNFa and IL-2, IFNc
and IL-2 or all three cytokines.
Median fluorescence intensity (MFI) assessments
The MFI for IFNc or TNFa for CD4 and CD8 monofunctional
and MFT cells was evaluated in the different vaccine groups using
the FlowJo software. For this study, the MFI is the fluorescence
intensity value representing the middle number of the distribution
of CD4 and CD8 T cells secreting only IFNc or TNFa, secreting
both IFNc and TNFa or cells secreting IFNc, TNFa and IL-2.
The data are presented as the mean of the individual MFI
assessments for 4–5 mice. The integrated MFI metric (iMFI) was
determined by multiplying the mean MFI values for a specific T
cell subset by its frequency.
Statistical analysis
The Graph Pad Prism 5 program was used to analyze the data
for these experiments (Graph Pad Software, San Diego CA). The
protection data, the CD4 and CD8 T cell flow cytometry results,
and the MFI data were evaluated using t test analysis. The
correlations between the iMFI values for triple positive cells and
the mean protection induced at 1 month post-challenge were
assessed using the Pearson correlation analysis.
Results
Characterization of vaccine-induced protective immunity
To assess whether the DmmaA4BCG deletion mutant formulated
with or without the DDA/TDB adjuvant induced superior anti-
tuberculosis protective immunity, the DmmaA4 BCG preparations
were tested in a mouse model of pulmonary TB. For the initial
studies, mice were vaccinated once subcutaneously with either
10
6 CFU of BCG Pasteur or the DmmaA4 BCG mutant.
Alternatively, mice were immunized three times with 10
6 CFU
of BCG Pasteur or the DmmaA4 BCG strain suspended in the
DDA/TDB adjuvant. At 2 months following the final vaccination,
the mice were aerogenically challenged with a low dose of virulent
M. tuberculosis Erdman. As seen in Experiment 1, all experimental
immunization procedures induced significant levels of protective
immunity (relative to controls) at 1 month post-challenge (Table 1).
Moreover, the protective responses elicited by immunization with
the BCG/adjuvant (21.35 log10) or the DmmaA4BCG/adjuvant
(21.75) vaccine formulations were significantly enhanced com-
pared to the live BCG control (20.73).
In a second study, we evaluated the longer term effectiveness of
these novel vaccine preparations. Again, at 1 month post-
challenge, all of the vaccine formulations induced significant
anti-tuberculosis protective immunity. Moreover, at the one
month time point, immunization with the DmmaA4BCG/Adjuvant
preparation (21.56 log10) evoked significantly elevated protective
responses compared to BCG alone (21.00). Similar results were
seen at 4 months post challenge. At this time point, all of the
vaccine preparations were protective relative to naives (p,0.05).
Furthermore, the DmmaA4BCG/adjuvant (22.12) and the BCG/
adjuvant (22.24) formulations were strikingly more protective
than BCG alone (20.90). It should be noted that one group of
mice was given BCG three times as a control in this study.
Interestingly, three doses of BCG did not evoke increased anti-
Table 1. Evaluation of the anti-tuberculosis protective
immunity induced by BCG strains formulated in DDA/TDB
adjuvant at one month and four months post-challenge.
Experiment 1
Group 1 Month 4 Months
Naive 5.4460.04
BCG 4.7160.07 (20.73)*
BCGA4 4.3760.19 (21.07)*
BCG/Adj 4.0960.16 (21.35)*#
BCGA4/Adj 3.7060.18 (21.74)*#‘
Experiment 2
Naive 4.9560.11 4.6760.13
BCG 3.9560.10 (21.00)* 3.7760.19 (20.90)*
BCG (36) 4.0560.12 (20.90)* ND
BCGA4 3.9460.21 (21.01)* 3.6860.06 (20.99)*
BCG/Adj 3.6060.25 (21.35)* 2.4360.25 (22.24)*#‘
BCGA4/Adj 3.3960.15 (21.56)*#‘ 2.5560.23 (22.12)*#‘
Experiment 3
Naive 4.6160.14 4.7460.20
BCG 3.6360.15 (20.98)* 3.6460.13 (21.10)*
BCGA4 3.6860.06 (20.93)* 3.8060.16 (20.94)*
BCG/Adj 2.8660.08 (21.75)*#‘ 3.1860.32 (21.56)*‘
BCGA4/Adj 2.4560.19 (22.16)*#‘ 3.0760.11 (21.67)*#‘
BCGA4/Adj=DmmaA4 BCG formulated in DDA/TDB adjuvant.
( ) The difference between naı ¨ve and experimental CFU.
ND – not done.
*Significantly decreased CFU values compared to naive controls, p,0.05.
#Significantly decreased CFU values relative to BCG, p,0.05.
‘Significantly decreased CFU values relative to BCGA4, p,0.05.
doi:10.1371/journal.pone.0032959.t001
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challenge when compared to a single BCG inoculation.
In a third study, vaccine-induced protective responses at one
and four months following a tuberculous infection were again
evaluated. At both time points, significantly decreased post-
challenge CFU levels were seen in all vaccine groups relative to
naı ¨ve controls (p,0.05). Additionally, immunization with both
adjuvant-containing vaccine formulations (BCG/adjuvant, 21.75;
DmmaA4BCG/adjuvant, 22.16) protected significantly better than
BCG (20.98) at 1 month post-challenge. Vaccination with the
DmmaA4BCG/adjuvant mixture (21.67) also yielded significantly
enhanced protective responses relative to BCG controls (21.10) at
4 months after an aerogenic challenge. Overall, in these three
separate studies, immunization with the BCG and DmmaA4BCG-
adjuvant formulations induced significantly increased anti-tuber-
culosis protective immunity compared to BCG controls in
response to a tuberculous infection by the aerosol route.
In a fourth experiment, we tested whether significant anti-
tuberculosis protective immunity could be generated in the lung
with a single dose of the DmmaA4BCG mutant strain formulated in
DDA/TDB adjuvant. As seen in Figure 1, a single dose of BCG or
the DmmaA4BCG/adjuvant yielded substantial protection at one
month post-challenge. However, at 2 months post-challenge, the
DmmaA4BCG/adjuvant preparation induced significantly in-
creased protection in the lung compared to BCG (20.70 log10
difference). Similarly, at 4 months post-challenge, significantly
better pulmonary protective immunity (20.84 log10 difference)
was detected in mice given a single dose of the DmmaA4BCG/
adjuvant mixture relative to BCG.
Analysis of vaccine-induced CD4 T cell immune
frequencies by flow cytometry
Vaccine-induced T cell responses were evaluated using multi-
parameter flow cytometry. At 2 months following the final
immunization, spleen cells were removed from the vaccinated
and naı ¨ve mice, stimulated overnight with BCG, stained for
intracellular cytokines, and analyzed by flow cytometry. Initial
analysis focused on CD4 T cell cytokine expression because CD4
T cells have been shown to be critical for controlling M. tuberculosis
infections in the mouse model [24]. As seen in Figure 2, all vaccine
preparations induced significantly increased frequencies of CD4 T
cells expressing IFNc, IFNc/TNFa and IFNc/TNFa/IL-2
relative to naı ¨ve controls. Interestingly, the frequencies of cells
secreting either TNFa or TNFa/IL-2 were only elevated
(compared to naı ¨ve controls) in spleen cultures recovered from
animals vaccinated with the adjuvanted BCG vaccine prepara-
tions. To identify the cellular responses which may be responsible
for the elevated levels of protection seen with the adjuvanted
vaccines, the CD4 T cell frequencies induced by immunization
with the adjuvanted preparations were compared to the cellular
frequencies evoked by vaccination with BCG. Immunization with
both the BCG/adjuvant and the DmmaA4BCG/adjuvant mixtures
induced significantly higher numbers of double-positive CD4 T
cells expressing TNFa/IL-2 than BCG (Figure 2B). Moreover,
immunization with the highly active DmmaA4BCG/adjuvant
preparation also induced elevated frequencies (relative to BCG)
of double positive CD4 T cells expressing IFNc/TNFa and triple-
positive cells secreting IFNc/TNFa/IL-2. To confirm these
findings, additional experiments were done to evaluate CD4 T
cell frequencies in BCG-vaccinated mice and mice immunized
with the DmmaA4BCG/adjuvant preparation (Figure S1). Again,
significantly higher frequencies of multifunctional CD4 T cells
expressing TNFa/IL-2 and triple positive CD4 T cells were
detected in splenocytes recovered from mice immunized with the
DmmaA4BCG/adjuvant preparation compared to BCG-vaccinated
mice.
Earlier studies have shown that CD4 T cells expressing multiple
cytokines often produce higher amounts of cytokines per cell than
monofunctional CD4 T cells [23,25,26]. To elucidate whether
vaccine-induced MFT cells produced elevated concentrations of
cytokines relative to monofunctional cells in these experiments, the
median fluorescent intensities (MFI) for IFNc and TNFa were
determined for relevant cell populations evaluated in these studies
(Figure 3A and B). However, for these experiments, the MFIs for
IL-2 were not systematically assessed because generally low levels
of IL-2 were detected in most studies. Consistent with previous
data, elevated MFI values for IFNc were detected in double-
positive IFNc/TNFa expressing CD4 T cells (3–7 fold increases)
and triple positive CD4 T cells (3.5–12 fold increases) recovered
from vaccinated mice compared to monofunctional IFNc
producing CD4 T cells from animals vaccinated with the same
vaccines (Figure 3A). For these MFT cells, the highest MFI CD4 T
cell values were again detected in mice vaccinated with the
DmmaA4BCG/adjuvant mixture.
To further evaluate vaccine-induced immune responses, the
total IFNc response of the populations of cytokine-producing CD4
T cells was assessed using the integrated MFI metric (iMFI) which
combines the magnitude and quality of T cell responses. Darrah et
al have previously shown that iMFI values (frequency6MFI) for
cells expressing IFNc, TNFa, and IL-2 correlated with the
protection induced by vaccines in a mouse model of Leishmania
[25]. For our studies, the IFNc iMFI values for IFNc, IFNc/
TNFa, and IFNc/TNFa/IL-2 producing cells induced by all of
the vaccine formulations were elevated at least 10 fold relative to
naı ¨ve controls (naı ¨ve iMFI data not shown). Furthermore, the
IFNc iMFI values were considerably elevated for the
DmmaA4BCG/adjuvant immunization groups compared to BCG
controls in each CD4 T cell subset evaluated. Increases relative to
BCG iMFI values of 8.4-fold for IFNc producing monfunctional
cells, 7.2 fold for IFNc/TNFa double positive cells and 5.3 fold for
triple positive CD4 T cells were detected in splenocytes from
Figure 1. Protection in C57BL/6 mice against a M. tuberculsosis
Erdman aerosol challenge after vaccination with either BCG or
the DmmaA4BCG/adjuvant formulation. Mice were challenged
with M. tuberculosis 8 weeks after a single s.c. immunization and then
were sacrificed 1, 2 or 4 months after the challenge for enumeration of
CFU’s in the lung. Significant CFU reduction relative to * naı ¨ve mice
(p,0.05) or
# BCG-vaccinated controls (p,0.05).
doi:10.1371/journal.pone.0032959.g001
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only IFNc, TNFa, or IL-2 or (B) CD4 MFT cells producing both IFNc and TNFa, IFNc and IL-2, TNFa and IL-2 or all three cytokines from
naı ¨ve or vaccinated mice. Splenocytes from three to five unchallenged mice per group were analyzed separately for these experiments.
* Significant differences relative to naı ¨ve controls (p,0.05).
# Significant differences compared to BCG-vaccinated mice (p,0.05).
doi:10.1371/journal.pone.0032959.g002
Figure 3. Median fluorescence intensity (MFI) of (A) IFNc or (B) TNFa in monofunctional or multifunctional CD4 T cells. The data are
presented as the mean of individual MFI values for 4–5 mice per vaccine group. * Significant differences relative to monofunctional cytokine
expressing cells, p,0.05.
# Significant differences relative to BCG in the same T cell subset, p,0.05.
doi:10.1371/journal.pone.0032959.g003
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ly, Pearson analysis showed that the correlation between vaccine-
induced CD4 IFNc iMFI values for triple positive cells and the
mean protection induced at 1 month post-challenge shows a trend
toward statistical significance (p=0.07).
Analysis of the CD4 T cell MFI values for TNFa again
demonstrated that multifunctional T cells express higher levels of
cytokines than monofunctional cells (Figure 3B). The MFIs for
TNFa were elevated about 2-fold for most experimental groups in
IFNc/TNFa expressing cells. Furthermore, striking 8–13 fold
increased TNFa MFI values were detected in triple positive CD4
T cells relative to corresponding monofunctional cells. Also, as
seen with IFNc iMFI’s, the iMFI values for TNFa were also
significantly elevated in IFNc/TNFa double positive CD4 T cells
from DmmaA4BCG/adjuvant vaccinated mice relative to CD4 T
cells from BCG-immunized mice (Figure S2B).
Analysis of vaccine-induced CD8 T cell immune
frequencies by multi-parameter flow cytometry
Although CD4 T cells have been shown to be essential for
controlling acute tuberculous infections in mice, CD8 T cells also
play a role in limiting chronic murine TB disease [24,27]. Using
flow cytometry, we also analyzed vaccine-induced CD8 multi-
functional T cell responses. As shown in Figure 4, immunization
with the live vaccines with or without adjuvant induced
significantly elevated frequencies of CD8 T cells expressing IFNc
(3–8 fold increases), IFNc/TNFa (5–11 fold) and IFNc/TNFa/
IL-2 (3–9 fold) relative to naı ¨ve controls. However, no significant
differences in vaccine-induced CD8 T cell frequencies were
detected among the experimental groups.
The CD8 T cell MFI for IFNc in this study were generally
consistent with the CD4 data; substantially higher MFI values
were usually seen in vaccine-induced multifunctional CD8 cells
than in cells expressing only IFNc Figure 5A). For example, 5–20
fold increased IFNc MFI values were detected in triple positive
CD8 T cells taken from animals vaccinated with the BCG, BCG/
adjuvant or DmmaA4BCG/adjuvant vaccines relative to corre-
sponding monofunctional cell populations. Importantly, the IFNc
MFI values were increased by 7 and 9 fold, respectively, in the
BCG/adjuvant and DmmaA4BCG/adjuvant preparations com-
pared to BCG controls in triple positive CD8 T cells. Similar to
the CD4 IFNc iMFI results, elevated IFNc iMFI values for the
DmmaA4BCG/adjuvant vaccine group were detected in each CD8
T cell subset (Figure S3A). Compared to BCG controls, CD8 iMFI
values were increased by 60-fold in monofunctional cells, 4.9 fold
in IFNc/TNFa producing T cells, and 33-fold in triple positive
cells in splenocytes recovered from animals immunized with the
DmmaA4BCG/adjuvant formulation.
Among the CD8 TNFa producing cells, the MFI values for the
adjuvanted vaccines were only significantly elevated relative to
nonadjuvanted BCG controls in triple positive cells (Figure 5B).
The TNFa iMFI values detected in these triple positive cells were
increased 30-fold for the BCG/adjuvant group and 15-fold for the
DmmaA4BCG/adjuvant immunized animals compared to BCG
controls (Figure S3B).
Vaccine safety in immunocompromised mice
The safety of immunizing HIV-infected children with live
vaccines, and particularly BCG, has become an increasing public
health concern [28,29]. Since new TB vaccines will be used in
some regions of the world with high HIV infection rates, the safety
of adjuvanted BCG preparations was evaluated by assessing their
capacity to proliferate in immunocompromised mice. In an initial
study, the mice were treated with an anti-IFNc antibody to reduce
IFNc concentrations and were then given one 10
6 CFU dose
subcutaneously of the control and adjuvant-containing mixtures.
In the spleens of non-treated naı ¨ve mice at 1 month post-infection,
nearly identical levels of BCG and the DmmaA4BCG mutant strain
Figure 4. The frequency (%) of (A) monofunctional or (B) multifunctional CD8 T cells in naı ¨ve and vaccinated mice as determined by
multiparameter flow cytometry analysis. * Statistical significance relative to naives, p,0.05.
doi:10.1371/journal.pone.0032959.g004
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without the DDA/TDB adjuvant (Figure 6A). In contrast,
significantly higher levels (.1 log10) of mycobacteria were detected
in the spleens of the BCG and DmmaA4BCG immunized IFNc
depleted mice relative to the BCG/adjuvant and DmmaA4BCG/
adjuvant infected immunodeficient mice at the 1 month time point
(p,0.05).
To further assess the safety of the adjuvanted BCG prepara-
tions, SCID mice were injected with BCG or the DmmaA4BCG
mutant as well as their adjuvanted vaccine counterparts. At 1
month post-vaccination, 5.5560.06 log10 CFU of BCG vaccine
and 5.1360.08 log10 CFU of the DmmaA4BCG mutant were
detected in the spleens of SCID mice (Figure 6B). In contrast,
compared to the non-adjuvanted controls, significantly lower CFU
(p,0.05) were recovered from the spleens of SCID mice
vaccinated with the BCG/adjuvant preparation (4.5860.07,
20.97 log10 reduction) or the DmmaA4BCG/adjuvant formulation
(4.7360.05, 20.40 log10 reduction).
Discussion
In recent years, the BCG prime/TB antigen boost immuni-
zation strategy has been a prominent strategy for improving the
effectiveness of vaccination against tuberculosis [11,12]. While
this approach is promising, it may be limited in developing
countries by potential concerns about the cost of producing
purified proteins, the safety of specific viral vectored vaccines (e.g.
adenovirus), and the complexities of prime/boost immunization
schedules. In this study, we have evaluated an alternative
relatively simple and cost effective TB vaccination strategy. This
approach combines the development of a mutant BCG strain
designed to enhance Th1 immune responses with lipid formu-
lation procedures [21]. We have shown in four separate
experiments that a mutant DmmaA4BCG strain formulated in
DDA/TDB adjuvant induced significantly elevated anti-tubercu-
losis protection relative to a BCG control at 1 and 4 months post-
challenge. These results are consistent with studies in at least five
different animal models which showed lipid encapsulation
increased the effectiveness of BCG vaccine in protecting against
tuberculosis [13–18].
The enhanced protection observed in our studies after
immunization with the adjuvant containing vaccines was associ-
ated with the induction of increased levels of multifunctional T
cells. In earlier studies, vaccine-induced amplification of MFT cells
has been shown to correlate with protection against L. major and
M. tuberculosis in mice as well as the control of SIV-viremia in non-
human primates [23,25,26,30]. Additionally, the presence of MFT
cells is characteristic of immune responses seen in non-progressive
HIV patients while HIV non-controllers generally elicit responses
dominated by monofunctional cytokine cellular responses [31].
One characteristic of MFT cells that has been associated with their
protective activity is their capacity to produce significant amounts
of IFNc and TNFa. Previous studies have demonstrated that
vaccine-induced CD4 MFT cells express 3–10 fold more IFNc
and/or TNFa than corresponding monofunctional CD4 T cells
producing only IFNc or TNFa [23,25,26]. Our MFI data and
iMFI calculations demonstrate that immunization with the
DmmaA4BCG/adjuvant preparation and to a lesser extent the
BCG/adjuvant formulation induces substantially elevated levels of
these cytokines relative to BCG controls. Our statistical analysis,
which showed that a trend in the correlation between iMFI values
for triple positive cells and vaccine-induced protection (p=0.07),
suggests an important role for MFT cells in the protection
mediated by the adjuvanted vaccines.
Figure 5. Median fluorescence intensity (MFI) of (A) IFNc or (B) TNFa in monofunctional or multifunctional CD8 T cells. The data are
presented as the mean of individual MFI values for 4–5 mice per vaccine group. *Statistical significance relative to monofunctional cytokine
expressing cells, p,0.05.
# Significant differences relative to BCG in the same T cell subset, p,0.05.
doi:10.1371/journal.pone.0032959.g005
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adjuvant and BCG/adjuvant formulations induced significantly
elevated levels (relative to BCG controls) of cells expressing both
TNFa and IL-2. Recently, Lindenstrom et al demonstrated that
vaccination with an Antigen 85-ESAT-6 fusion protein formulated
in DDA/TDB adjuvant also elicited high levels of TNFa/IL-2
producing cells, a long-lived central memory cell population [32].
Orme has recently speculated that the Achilles heel of BCG is its
inability to induce high numbers of central memory T cells [33].
Although BCG is very effective in inducing effector memory cells
in lungs, it is relatively ineffective at evoking the more persistent,
faster reacting central memory cells. The enhanced capacity of
DmmaA4BCG/adjuvant and BCG/adjuvant vaccine formulations
to induce elevated concentrations of the TNFa/IL-2 producing
central memory T cells may contribute to the increased anti-
tuberculosis protection seen after immunization with these
preparations. Clearly, further studies are needed to evaluate the
role of the TNFa/IL-2 expressing cells in the maintenance of long-
term anti-tuberculosis cellular responses induced by BCG-
containing vaccines.
The biological basis of the enhanced immunogenicity of the
DmmaA4BCG/adjuvant vaccine is likely multi-factorial. First, the
DDA/TDB adjuvant is known to be effective in generating Th1
and Th17 T cell responses [34,35]. DDA is a synthetic amphiphile
which forms cationic liposomes. Encapsulation of antigen within
these liposomal structures can promote a depot effect leading to
enhanced antigen persistence and increased monocyte influx into
the injection site. The presence of the immunostimulatory TDB in
the liposomes should also improve their drainage into the lymph
nodes and enhance monocyte infiltration. Second, emulsifying
BCG in the DDA/TDB adjuvant likely impacts the kinetics of
BCG survival and the location of persisting BCG infections [15].
In oral vaccination studies, lipid encapsulation of BCG was shown
to extend its persistence in vivo. Furthermore, formulating BCG in
lipids may lead to more efficient delivery of live bacilli to sites of
immune induction. Given that recent experiments have shown
that clearance of M. tuberculosis by chemotherapy permits
expansion of central memory T cells, changing the location and
persistence of BCG by lipid encapsulation could significantly alter
the relative proportion of vaccine-induced effector and central
memory cells [36]. Our flow cytometry data, including the relative
expansion of the central memory CD4 T cell subset expressing
TNFa and IL-2 seen after immunization with the DmmaA4BCG/
adjuvant vaccine, support this hypothesis. Surprisingly although
the deletion of the mmaA4 gene from M. tuberculosis has been shown
in vitro to reverse repression of IL-12 production, we were unable
to detect elevated splenocyte IL-12 message levels by RT-PCR
after vaccination with the Dmma4A4BCG deletion mutant
formulated with or without adjuvant. The reasons for the absence
of Dmma4A4BCG vaccine induced IL-12 message expression are
uncertain but may result because of differences between the
Dmma4A4 M. tuberculosis and Dmma4A4BCG mutants or may reflect
Figure 6. Reduced BCG splenic CFU levels one month after treatment of immunocompromised mice with the adjuvanted BCG
preparations. A. Mice were given two i.p. injections of anti-IFNc mAb (black bars) two days apart before receiving a single 10
6 CFU dose of either
BCG or DmmaA4BCG with or without adjuvant. Untreated mice served as infection controls (gray bars). The antibody treatment was repeated every
10 days until the mice were sacrificed one month post-infection to quantify the splenic BCG CFU. B. SCID mice were injected with a single 10
6 CFU
dose of either BCG or DmmaA4BCG with or without adjuvant. One month after the injection, splenic bacterial burdens were determined. *Significant
differences relative to adjuvanted BCG controls, p,0.05.
doi:10.1371/journal.pone.0032959.g006
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Alternatively, the increased IL-12 expression that has been
previously observed in vitro [21] most likely occurs in microen-
vironments in vivo that may not be detectable by current methods.
Several recent published reports have shown that HIV-infected
infants are highly vulnerable to disseminated BCG infections.
Studies in South Africa and Argentina have indicated that the risk
of vaccine-related disease after BCG immunization of HIV-
infected children can be as high as one percent [28]. Consequent-
ly, the WHO has recommended that BCG should not be
administered to HIV-infected children [29]. Surprisingly, in
addition to being more immunogenic, we showed that the
adjuvant containing BCG vaccines may also be safer. In
immunocompromised mice that had been given identical doses
of vaccine, approximately 5–10 fold lower concentrations of
mycobacteria were detected in mice injected with the
DmmaA4BCG/adjuvant and BCG/adjuvant formulations relative
to non-adjuvanted controls. The mechanisms associated with the
enhanced safety of the adjuvanted live vaccines in interferon-
depleted animals and SCID mice are unknown but could result
from either differential tissue sequestration or reduced proliferative
rates of BCG suspended in the DDA/TDB mixture. Given that
one-fourth of infants born in some African countries will likely be
born to HIV-infected mothers, it is imperative that vaccine safety
concerns related to BCG immunization be emphasized and fully
evaluated as new TB vaccination strategies are being developed
[37,38].
In sum, we have shown vaccines prepared by mixing either
BCG Pasteur or a DmmaA4 mutant BCG strain with DDA/TDB
adjuvant yielded safer formulations that induced significantly more
anti-tuberculosis protective immunity than BCG controls. With
increasing pressure to develop inexpensive, safe, and more
immunogenic TB vaccination strategies, further studies are
urgently needed to confirm the increased safety and immunoge-
nicity of these adjuvanted BCG formulations.
Supporting Information
Figure S1 To verify the multifunctional T cell frequency
results that were observed in the initial experiments, a
separate group of mice were vaccinated with BCG or
BCG-A4/Adj and the frequencies (%) of CD4 (A) or CD8
(B) multifunctional T cells producing IFNc and TNFa,
IFNc and IL-2, TNFa and IL-2 or all three cytokines (TP)
were measured by flow cytometry. Splenocytes from four
unchallenged mice per group were analyzed separately. *Signif-
icant differences relative to naı ¨ve controls, p,0.05.
#Significant
differences relative to BCG controls, p,0.05.
(TIF)
Figure S2 The integrated MFI (iMFI) values for (A) IFNc
and (B) TNFa were calculated by multiplying the MFI
values times the frequencies of IFNc or TNFa single
positive, IFNc/TNFa double positive or triple positive
(IFNc/TNFa/IL-2) CD4 T cells. iMFI values were derived
from stimulated splenocytes from BCG, BCG/Adj. BCG-A4 or
BCG-A4/Adj vaccinated mice.
#Significant differences relative to
BCG controls, p,0.05.
(TIF)
Figure S3 The iMFI values for (A) IFNc and (B) TNFa
are shown for IFNc or TNFa single positive, IFNc/TNFa
double positive or triple positive (IFNc/TNFa/IL-2) CD8
T cells using stimulated splenocytes from BCG, BCG/
Adj. BCG-A4 or BCG-A4/Adj vaccinated mice.
#Significant
differences relative to BCG controls, p,0.05.
(TIF)
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